NMN Supplementation for IVF Failure Patients

This clinical study focuses on improving the chances of success for people undergoing in vitro fertilization (IVF) who have faced previous failures. It investigates the use of a compound called Nicotinamide mononucleotide (NMN), which has shown promise in enhancing the quality of eggs in older individuals by supporting energy production and reducing cellular damage. The study is important because recurrent IVF failures can have significant emotional and financial impacts, and finding effective ways to improve egg quality may enhance the success rate of these fertility treatments. Participants in this study will take part in a trial where they are randomly assigned to receive either the NMN supplement or a placebo, without knowing which one they are getting, to ensure unbiased results. The supplement is given orally in a daily dose of 900 mg. Researchers will monitor the effects of NMN on IVF outcomes by evaluating the quality of eggs and embryos. The study aims to determine if NMN can indeed improve the chances of successful fertilization and pregnancy for those who have previously experienced challenges with IVF.